Management of pouch-vaginal fistulas - experience from our institution

P C Sivathondan1, A Bloemendaal1, S Travis2

  • 1Oxford Colorectal Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.

Insights

Pouch-vaginal fistula (PVF) management remains challenging, with healing and gastrointestinal continuity rates around 50%. Anti-tumour necrosis factor (anti-TNF) therapy shows promise for late-presenting PVF and cases with Crohn's disease features.

Area of Science:

  • Gastroenterology
  • Colorectal Surgery
  • Surgical Complications

Background:

  • Pouch-vaginal fistula (PVF) is a rare but severe complication following ileo-anal pouch reconstruction.
  • Effective management strategies for PVF are crucial for patient outcomes.

Purpose of the Study:

  • To review recent management approaches for PVF.
  • To evaluate the role of anti-tumour necrosis factor (anti-TNF) drugs in PVF treatment.

Main Methods:

  • A retrospective review of 23 patients with PVF managed between 2007 and 2016.
  • Data collected included original surgery details, PVF presentation, management, and outcomes, with a median follow-up of 6 years.
  • Primary outcome was achieving gastrointestinal continuity, defined by the absence of a stoma.

Main Results:

  • Overall healing and gastrointestinal continuity rates were 52% (12/23 patients).
  • Pelvic sepsis at initial surgery was significantly associated with the need for a long-term ileostomy (P=0.009).
  • Anti-TNF therapy was used in 12 patients, with 7 achieving GI continuity. Benefit was observed in late-presenting PVF and Crohn's-like disease.

Conclusions:

  • PVF presents a significant surgical challenge with limited success rates for healing and GI continuity.
  • Anti-TNF therapy may offer a beneficial treatment option for specific PVF patient subgroups, including those with late presentation or Crohn's disease features.
Abstract